In vitro exposure of living skeletal muscle to ryanodine has been proposed as a potentially specific test for malignant hyperthermia (MH) Both of the two widely used procedures for the diagnosis of malignant hyperthermia (MH) susceptibility using in vitro contracture tests (IVCT) with living skeletal muscle [1, 2] use separate exposure to halothane and to caffeine. The regimen of the North American MH Group also allows for a combined caffeine-halothane test [2] , but recently this has been invalidated because of a high incidence of false positive results [3, 4] . The separate-exposure halothane and caffeine tests also have imperfections. Results of IVCT performed in patients with a low risk of MH ("controls") suggest a false positive rate of approximately 4 % using the European procedure [5] and 9 % using the North American procedure [3] . In our series of more than 2400 tests, 14% of patients with an abnormal response to halothane reacted normally to caffeine, indicating the caffeine test lacks total sensitivity. Both procedures are associated also with lack of specificity, in that muscle from patients with myopathies other than MHS develop abnormal contracture responses [6, 7] . It was for these reasons, and with the need for the most accurate phenotyping of MH susceptibility for successful genetic analysis of the condition, that we investigated the potential of the plant alkaloid, ryanodine, for use in IVCT. The early results of our ryanodine contracture test were encouraging and were presented as a preliminary report [8] .
Both of the two widely used procedures for the diagnosis of malignant hyperthermia (MH) susceptibility using in vitro contracture tests (IVCT) with living skeletal muscle [1, 2] use separate exposure to halothane and to caffeine. The regimen of the North American MH Group also allows for a combined caffeine-halothane test [2] , but recently this has been invalidated because of a high incidence of false positive results [3, 4] . The separate-exposure halothane and caffeine tests also have imperfections. Results of IVCT performed in patients with a low risk of MH ("controls") suggest a false positive rate of approximately 4 % using the European procedure [5] and 9 % using the North American procedure [3] . In our series of more than 2400 tests, 14% of patients with an abnormal response to halothane reacted normally to caffeine, indicating the caffeine test lacks total sensitivity. Both procedures are associated also with lack of specificity, in that muscle from patients with myopathies other than MHS develop abnormal contracture responses [6, 7] . It was for these reasons, and with the need for the most accurate phenotyping of MH susceptibility for successful genetic analysis of the condition, that we investigated the potential of the plant alkaloid, ryanodine, for use in IVCT. The early results of our ryanodine contracture test were encouraging and were presented as a preliminary report [8] .
We now present results from 155 patients attending for diagnosis of their MH status, on whose muscle IVCT have been done using halothane, caffeine and ryanodine. In a similar way, we also investigated muscle specimens from six patients with other neuromuscular disorders.
PATIENTS AND METHODS

Patients uLUriding for irrvcstigation of MH status
Muscle specimens were obtained by open biopsy of the vastus medialis under regional anaesthesia (3 in 1 block) or general anaesthesia (thiopentone, fentanyl and nitrous oxide in oxygen) and maintained and used for diagnostic IVCT according to the European MH Group procedure [1] . MH status was assigned in the usual way using suitably viable specimens (twitch response > 1 g): abnormal responses to halothane (> 0.2 g contracture with ^ 2 % halothane) and caffeine (>0.2g contracture with caffeine < 2 mmol litre" 1 ) indicates MH susceptible (MHS); abnormal response to only one of either halothane or caffeine indicates MH equivocal (MHE); normal responses to both drugs indicate non-susceptibility (MHN). Any muscle fascicle surplus to diagnostic requirements was used for a ryanodine contracture test (RCT). The first 63 of these were performed as described previously [8] with ryanodine added in increments at 3-min intervals to achieve muscle bath concentrations of 0.4,0.8,1.6 and 10 nmol litre" 1 (RCT version 1). For the remaining 92 patients, additional ryanodine concentrations of 3.2 and 6.4 umol litre" 1 were included (RCT version 2). The RCT was modified in an attempt to produce a clear distinction in ryanodine threshold concentration between MHS and MHN groups. Initially, the threshold value of ryanodine was determined as that concentration of ryanodine at which a contracture of 0.2 g developed. This was soon changed to the concentration of ryanodine at which a sustained contracture commenced. The results presented here use this later definition for threshold value of ryanodine. For Ryanodine was added in increments at 3-min intervals to achieve muscle bath concentrations of 0.4, 0.8, 1.6 and 10 umol litre"
1 . The threshold value of ryanodine was determined as that concentration of ryanodine at which a sustained contracture commenced. If no contracture had developed within 3 min of exposure to ryanodine 10 umol litre" 1 , this concentration was maintained until a contracture did develop and the contracture threshold expressed as the time (in minutes) after exposure to ryanodine 10 umol litre" 1 .
version 1 of the RCT, where no contracture had developed within 3 min of exposure to ryanodine 10 |imol litre" 1 , this concentration was maintained until a contracture did develop and the contracture threshold expressed as the time (in minutes) after exposure to ryanodine 10 umol litre" 1 .
Patients with other neuromnscular disorders
Six patients attending for muscle biopsy for histological diagnosis of a clinical neuromuscular disease were included. Surplus tissue was used for halothane, caffeine and ryanodine contracture tests that were performed as for the MH patients.
The ryanodine used (ryanodine dehydroryanodine, 98 % pure) was obtained from Agri Systems Chemicals (Philadelphia, U.S.A.).
RESULTS
Patients attending for investigation of MH status
RCT version 1 ( fig. 1 ). Of the 63 patients investigated, 27 were classified as MHS, 30 as MHN and six as MHE. All the MHS muscle fascicles developed a contracture within 3 min of exposure to the greatest concentration of ryanodine (10 (imol litre" 1 was poorly viable (twitch response = 0.1 g). The halothane, caffeine and ryanodine thresholds for the important group of patients classified as MHE are shown in table I. The relationships between the thresholds in individual patients for halothane, caffeine and ryanodine (version 2) contracture tests (HCT, CCT and RCT respectively), as indicated by the Spearman rank correlation coefficient (rs) were: HCT vs RCT, rs = 0.737 (P < 0.001); CCT vs RCT, rs = 0.736 (P < 0.001); HCT vs CCT, rs = 0.787 (P < 0.001).
Patients with other neuromuscular disorders
Histological diagnosis and details of results of halothane, caffeine and ryanodine contracture tests are shown in table II. There was insufficient muscle for a caffeine contracture test in one patient.
DISCUSSION
The results of the diagnostic investigations for MH susceptibility in the 155 patients studied here are typical for our laboratory, with 34% classified as MHS, 13% MHE and 53% MHN. When the European MH Group procedure was agreed, there was a consensus that it was far more important, from a clinical perspective, to avoid false negative rather than false positive diagnoses. As one of the purposes of this process was to enable validation of results and research between European laboratories, it was necessary to set criteria for recognition of true MH positive and true MH negative patients that became, respectively, the MHS and MHN categories. It was perhaps unfortunate, and the cause of considerable confusion since, that those patients not meeting the criteria for MHS or MHN were labelled "equivocal". While this group of patients, probably, does include those with false positive results (true equivocals), the European Group's study of low risk patients indicated a false positive rate of about 4 % [5] . This suggests that the majority of the MHE patients are susceptible to MH. In our laboratory, all MHE patients respond abnormally to halothane and it is our contention that this large MHE group is, therefore, a reflection of the lack of sensitivity of the caeffeine contracture test rather than a lack of specificity of the halothane contracture test. It should be noted, however, that in some centres MHE status results from an abnormal caffeine response with normal halothane response.
However, these points were only of academic importance with respect to the original goals of the European MH Group. Clinically, MHE patients usually were (and still are) regarded as susceptible to MH, but only MHS and MHN patients are entered in research programmes. Since 1984 there have been major and rapid advances in the field of molecular biology that have resulted in the real prospect of identifying the gene defect(s) responsible for MH. The nature of the required linkage studies was described elegantly by Levitt and colleagues [9] , but the critical point is that their accuracy is dependent entirely on the accurate phenotyping of as many individuals as possible from MH families by IVCT. For these studies it is essential, therefore, that the numbers of false positive, false negative and doubtful IVCT diagnoses are minimized. To achieve this, it is clear that the MHE classification must be redressed. Experience with the European MH Group procedure has demonstrated that positive results in two distinct tests increase the statistical confidence of the diagnosis of susceptibility to MH. This principle logically might be extended by the addition of a third test. Examination of the results obtained using RCT version 2 indicates that this warrants consideration for use as such a third test. If a ryanodine threshold of 3.2 umol litre" 1 or less is taken as an abnormal result, the RCT successfully identified the MHS patients (excluding the result obtained with poorly viable muscle). Furthermore, if one assumes that the MHN group are true negatives (which is highly likely), the RCT has a false positive rate of 5.8% (99 % confidence interval of -2.5 % to 14.1 %). The most exciting aspect of the RCT, however, is that it appears to identify two populations within the MHE group, which suggests it does have the potential to distinguish positive and negative patients within this group. From this study, it is possible to conclude the following about individual MHE patients: a ryanodine threshold of 1.6 umol litre" 1 indicates MH susceptibility with near certainty; a ryanodine threshold of 3.2 umol litre" 1 indicates a probability of at least 85 % of MH susceptibility; a ryanodine threshold of 10 umol litre" 1 indicates almost certainly non-susceptibility to MH. Although no MHS patient (with viable specimen) had a ryanodine threshold greater than 3.2 umol litre" 1 , an insufficient number of MHS patients has been studied to permit the conclusion that MHE patients with a ryanodine threshold of 6.4 umol litre" 1 are not susceptible. However, the lower limit of the 99% confidence interval for the probability that patients with a ryanodine threshold of 6.4 umol litre" 1 are not susceptible is 83%.
MacKenzie and colleagues [10] have suggested that the threshold force of contracture for the halothane contracture test is too low. From the results shown in table I, it can be seen that it would be unwise to increase the threshold force of contracture at 2 % halothane to more than 0.2 g as, of the five patients with muscle reaching no greater force, three had a ryanodine threshold of 3.2 umol litre" 1 , while one had a normal response to ryanodine (threshold of 10 umol litre" 1 ). The specimen from the fifth such patient for the RCT was poorly viable. Of course, if must be noted that the RCT may be unreliable with poorly viable specimens and we would recommend that, as stipulated in the European MH Group procedure for halothane and caeffeine tests, muscle specimens must have a twitch response of at least 1 g.
The IVCT results from muscle of patients with other neuromuscular disorders (table II) confirm earlier studies [6, 7] which demonstrated that neither halothane or caffeine contracture tests are specific for MH. The present results also show that the RCT is also not specific for MH. That the most abnormal response with the RCT was seen in denervated muscle suggests the RCT is able to detect some forms of diseased muscle (primary and secondary conditions), rather than only those caused by an abnormal ryanodine receptor protein (sarcoplasmic reticulum calcium release channel). Results of the RCT, therefore, are consistent with the hypothesis that MH is caused by an abnormal ryanodine receptor protein gene [11, 12] , but equally consistent with MH being a genetically heterogeneous condition [13] .
